Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study (MIViral)

University Hospitals (UH) logo

University Hospitals (UH)

Status

Active, not recruiting

Conditions

RSV Infection
SARS-CoV-2 Infection
Virus Shedding
Mucosal Immunity
Influenza Viral Infections

Treatments

Other: No intervention

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT05794412
2022-01722

Details and patient eligibility

About

The goal of this observational study is to learn about the influence of pre-existing mucosal immunity, i.e. antibodies and immune cells that are present at the nasal mucosa before infection, on the infectious viral load after infection with SARS-CoV-2, influenza virus and RSV. The investigators will include app. 320 participants which will be followed for up to 17 months. During this time, the investigators will monitor their nasal mucosal antibodies at regular intervals and compare them to their infectious viral load if they are infected with SARS-CoV-2, influenza virus or RSV. Participants are invited to take a test for SARS-CoV-2, influenza virus or RSV in case of respiratory symptoms. If participants are positive the investigators will follow their viral load kinetics by taking nasopharyngeal swabs every 2-3 days. The investigators will also record the duration and strength of the following symptoms: Cough Fever Tired Sore throat Difficulty breathing Respiratory distress Headache Loss (or alteration) of smell Loss (or alteration) of sense of taste Myalgias Chills Subjective fever Pink sputum (or coughing up blood) Thoracic pain Runny nose Abdominal pain Nausea Vomiting Diarrhea Constipation Irritated or watery eyes Rashes Other

Enrollment

320 patients

Sex

All

Ages

18 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • In general good health, as determined by study investigators
  • All participants must be living in the canton of Geneva or working/studying in the canton of Geneva and living in neighboring communities that are within one hour travelling distance by car.

Exclusion criteria

  • Inability to provide written consent.
  • Severely immunocompromised subjects as determined by the study investigator
  • Treated with inhaled drugs by nasal route within the last month

Trial contacts and locations

0

Loading...

Central trial contact

Isabella Eckerle, Prof.; Benjamin Meyer, Dr.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems